Cosmos Health Secures Improved Terms in Acquisition of ZipDoctor from American International Holdings
January 28, 2023
Trending News ☀️
Cosmos Health ($NASDAQ:COSM), a publicly traded healthcare technology company, announced on Friday that it had successfully renegotiated the terms of its acquisition of ZipDoctor from American International Holdings. The company was able to extend and update the agreement, as well as secure improved payment terms and a revised purchase price. This letter of intent will now be valid until February 1st. Cosmos Health is a healthcare technology company that specializes in providing innovative solutions to empower healthcare providers to deliver better patient care. The company provides cloud-based technology to enable healthcare providers to coordinate care, monitor patient outcomes, and improve the overall quality of care. With their acquisition of ZipDoctor, Cosmos Health aims to expand their offerings and grow their footprint in the healthcare technology market. ZipDoctor is a telemedicine platform that provides medical services virtually through an app. Patients can use the app to book an appointment with a doctor and receive diagnosis and treatment for minor medical issues such as colds, flu, and sinus infections.
With the acquisition of ZipDoctor, Cosmos Health hopes to leverage their existing technology to enhance their current offerings and offer additional telemedicine services. With the renewed agreement, Cosmos Health will pay a revised purchase price and gain improved payment terms. The new agreement is valid until February 1st and gives the company time to work out all the details of the acquisition. This acquisition will help Cosmos Health grow their presence in the healthcare technology sector and increase their customer base. The acquisition of ZipDoctor is an important step for Cosmos Health as they continue to expand their offerings and improve patient care. The improved terms and conditions of the agreement will help the company secure the necessary funds to make this acquisition a success. As the healthcare industry continues to evolve, Cosmos Health is well positioned to capitalize on the growing demand for telemedicine services.
Share Price
This is a major move for the company, as it secures improved terms in the deal. As a result, COSMOS HEALTH‘s stock opened at $4.8 and closed at $4.9, a drop of 8.3% from its previous closing price of 5.3. The acquisition of ZipDoctor will help COSMOS HEALTH expand its presence in the healthcare sector and tap into new market opportunities. It will also help the company leverage AIH’s extensive resources and expertise to gain an edge in the industry. The acquisition will give COSMOS HEALTH access to ZipDoctor’s cutting-edge technology and network of medical professionals. This will enable the company to provide better healthcare services to its customers and increase its customer base.
Additionally, the improved terms of the deal will also help COSMOS HEALTH reduce its operational costs and improve its profitability. By securing improved terms in the deal, COSMOS HEALTH is able to gain a competitive advantage over its rivals in the healthcare sector. This will help the company tap into new market opportunities and provide better services to its customers. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cosmos Health. More…
| Total Revenues | Net Income | Net Margin |
| 54.47 | -34.95 | -7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cosmos Health. More…
| Operations | Investing | Financing |
| -6.1 | -0.06 | 5.27 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cosmos Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 45.62 | 40.47 | 0.2 |
Key Ratios Snapshot
Some of the financial key ratios for Cosmos Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.2% | – | -1.4% |
| FCF Margin | ROE | ROA |
| -11.9% | -7.0% | -1.0% |
VI Analysis
Company fundamentals are a reflection of its long term potential, and the VI app simplifies the analysis of companies such as COSMOS HEALTH. According to the VI Star Chart, COSMOS HEALTH has a relatively low health score of 2/10 due to its cashflows and debts. This indicates that COSMOS HEALTH is less likely to be able to sustain future operations in times of crisis. COSMOS HEALTH is strong in growth, medium in assets, profitability and weak in dividends. Thus, it is classified as a ‘cheetah’ company, which is defined as one that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be of interest to investors who are looking for high-risk, high-reward investments. They must recognize the risks involved and have a good understanding of the company’s fundamentals, such as its cashflows and debts. Such investors may also be interested in investing in COSMOS HEALTH specifically due to its strong growth prospects. More…
VI Peers
In the global market for pharmaceuticals, there are many companies vying for market share. Among these is Cosmos Holdings Inc, which competes against ApicHope Pharmaceutical Co Ltd, Anxo Pharmaceutical Co Ltd, and Harbin Gloria Pharmaceuticals Co Ltd. All of these companies are striving to develop and market the most effective drugs and treatments possible in order to stay ahead of the competition and maintain their respective shares of the market.
– ApicHope Pharmaceutical Co Ltd ($SZSE:300723)
ApicHope Pharmaceutical Co Ltd is a company that manufactures and sells pharmaceutical products. The company has a market cap of 7.8B as of 2022 and a return on equity of 14.23%. ApicHope Pharmaceutical Co Ltd is a company that is dedicated to providing quality pharmaceutical products to its customers. The company has a strong commitment to research and development, and this has led to the development of new and innovative products that meet the needs of its customers. ApicHope Pharmaceutical Co Ltd is a company that is committed to providing its customers with the best possible products and services. The company has a team of highly skilled and experienced professionals who are dedicated to providing the best possible products and services to its customers.
– Anxo Pharmaceutical Co Ltd ($TPEX:6677)
Anxo Pharmaceutical Co Ltd is a biopharmaceutical company that focuses on the research and development of novel drugs and therapies. The company has a market cap of 1.01B as of 2022 and a Return on Equity of -1.19%. The company’s products are designed to treat a variety of conditions, including cancer, infectious diseases, and inflammatory disorders.
– Harbin Gloria Pharmaceuticals Co Ltd ($SZSE:002437)
Harbin Gloria Pharmaceuticals Co Ltd is a Chinese company with a market cap of 5.87B as of 2022. The company’s Return on Equity (ROE) is 2.28%. Harbin Gloria Pharmaceuticals is engaged in the research, development, production, and sale of pharmaceutical products. The company’s products include western medicines, Chinese medicines, and medical devices. Harbin Gloria Pharmaceuticals has a strong research and development team and a large-scale production base. The company’s products are sold in China and internationally.
Summary
Cosmos Health has recently acquired ZipDoctor from American International Holdings and the terms of the acquisition have been improved. This could be a good move for investors in Cosmos Health, as it will provide them with access to ZipDoctor’s innovative technology which could help the company to expand its market share. However, the stock price of Cosmos Health moved down the same day, suggesting that investors were not entirely enthused by the news. In order to make a decision, investors should research the deal further, analyze the financials of both companies, and consider whether or not they believe the acquisition will be beneficial in the long term.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
